South Korea's Ministry of Food and Drug Safety (MFDS) has pre-announced the list of sterile injectable products subject to equivalence re-evaluation in 2027, prompting pharmaceutical companies to assess the financial burden of data submission. Many low-margin products may be voluntarily withdrawn, reshaping the supply landscape for injectable solutions, suspensions, and emulsions relevant to medical aesthetics clinics.
Regulatory timeline
MFDS recently notified the industry of the 2027 re-evaluation scope, covering solution injections, suspension injections, and emulsion injections under classification numbers 400 (excluding 431), 600, 700, and 800. The official notice is scheduled for October 2026, with a deadline of June 30 for companies to submit requests for product exclusion.
Re-evaluation requirements
Equivalence re-evaluation requires manufacturers to submit physicochemical equivalence data or clinical data to re-verify the quality and performance of products containing the same active ingredient. The process is particularly demanding for injectables, which face stricter manufacturing facility and quality control standards compared to oral formulations.
Market impact and voluntary withdrawals
In previous sterile injectable re-evaluation rounds, the number of target products significantly decreased as many companies chose voluntary withdrawal rather than bear the cost of data preparation. Industry sources indicate that products with low sales volumes or effectively discontinued distribution are most likely to be withdrawn. An industry insider commented, "The bigger variable is not the re-evaluation itself but the cost of data preparation and business feasibility review."
What buyers should watch
Overseas importers and distributors sourcing sterile injectables from South Korea should monitor the final re-evaluation list expected in October 2026. Products that are voluntarily withdrawn may disappear from the market, potentially affecting supply continuity for aesthetic injectables such as fillers, botulinum toxin, and other sterile solutions. Buyers are advised to verify the re-evaluation status of their current or planned product lines with Korean suppliers.
Sourcing context
The MFDS has broadened the criteria for exclusion from re-evaluation, including original drugs, products under re-examination, designated comparator products, and fully contract-manufactured items. This flexibility may allow some products to remain on the market without full re-evaluation, but companies are still reviewing their portfolios. The final outcome will shape the availability of sterile injectables in the Korean market and for export.
Source: Read the original report | Published: June 15, 2026